Allspring Global Investments Holdings LLC Buys New Shares in Akoya Biosciences, Inc. (NASDAQ:AKYA)

Allspring Global Investments Holdings LLC acquired a new position in shares of Akoya Biosciences, Inc. (NASDAQ:AKYAGet Rating) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 489,075 shares of the company’s stock, valued at approximately $7,487,000. Allspring Global Investments Holdings LLC owned approximately 1.31% of Akoya Biosciences at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Morgan Stanley bought a new position in shares of Akoya Biosciences during the second quarter worth $2,138,000. Bank of America Corp DE bought a new stake in Akoya Biosciences in the 2nd quarter valued at about $93,000. Citadel Advisors LLC bought a new stake in shares of Akoya Biosciences during the 2nd quarter worth approximately $883,000. Candriam Luxembourg S.C.A. acquired a new position in Akoya Biosciences during the 3rd quarter worth approximately $590,000. Finally, Geode Capital Management LLC increased its position in Akoya Biosciences by 6.4% during the 3rd quarter. Geode Capital Management LLC now owns 133,772 shares of the company’s stock worth $1,867,000 after purchasing an additional 8,074 shares in the last quarter. 27.63% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Akoya Biosciences from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 17th. Piper Sandler dropped their target price on shares of Akoya Biosciences from $23.00 to $18.00 and set an “overweight” rating for the company in a research report on Thursday, March 17th. Finally, Morgan Stanley lowered their price objective on shares of Akoya Biosciences from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, March 15th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from, the stock has an average rating of “Buy” and a consensus target price of $21.25.

NASDAQ AKYA opened at $10.51 on Monday. The company has a market cap of $393.86 million and a P/E ratio of -2.33. The firm’s 50 day moving average price is $11.27. Akoya Biosciences, Inc. has a one year low of $9.53 and a one year high of $28.96. The company has a quick ratio of 4.76, a current ratio of 5.09 and a debt-to-equity ratio of 0.27.

Akoya Biosciences (NASDAQ:AKYAGet Rating) last announced its quarterly earnings results on Monday, March 14th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.16). Akoya Biosciences had a negative net margin of 78.18% and a negative return on equity of 47.57%. On average, equities analysts expect that Akoya Biosciences, Inc. will post -1.29 EPS for the current fiscal year.

About Akoya Biosciences (Get Rating)

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. It offers single-cell resolution with spatial context that provides a wealth of information to visualize tissue organization and disease pathology on a molecular level to understand disease progression and treatment response.

See Also

Want to see what other hedge funds are holding AKYA? Visit to get the latest 13F filings and insider trades for Akoya Biosciences, Inc. (NASDAQ:AKYAGet Rating).

Institutional Ownership by Quarter for Akoya Biosciences (NASDAQ:AKYA)

Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with's FREE daily email newsletter.